Pouya Mohajer MD LTD

Pouya Mohajer MD LTD was paid $2.74M by Medicaid between Jan 2018 and Dec 2024, across 30 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 66% of everything it billed.

33Billing provider infoPOUYA MOHAJER MD LTD
LAS VEGAS, NV 89148

33aNPI1902826464assigned 07/20/2006

33bProvider typePain Medicine (Anesthesiology) Physician

28Total paid$2.74M

24GClaims91,583

24DCodes billed30

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other Pain Medicine (Anesthesiology) Physician providers in Nevada

Rank by total paid#4 of 21

Median peer was paid$130K

This provider vs. median21×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	4,612	$94K
2019	17,302	$348K
2020	13,285	$403K
2021	17,993	$538K
2022	12,225	$427K
2023	14,783	$484K
2024incomplete	11,383	$447K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	66%	38,495	34,741	$1.80M
J3300	Injection, triamcinolone acetonide, preservative free, 1 mg	12%	2,496	1,258	$321K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	8.5%	5,228	4,368	$234K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	5.3%	2,432	1,957	$145K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	4.3%	5,440	4,303	$119K
99203	Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity	1.4%	503	469	$38K
64483		<1%	315	217	$25K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	1,050	840	$22K
64635		<1%	117	75	$13K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	5,236	3,565	$10K
64636		<1%	117	75	$4K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	8,909	5,889	$3K

18 more codes

99204	Doctor's office visit, new patient (more involved)	<1%	43	$3K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	7,292	$3K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	1,018	$2K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	6,953	$1K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	15	$673.79
20610		<1%	14	$487.01
J2175	Injection, meperidine hydrochloride, per 100 mg	<1%	253	$188.21
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	379	$102.76
99072		<1%	1,926	$3.60
G8427	Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications	0%	1,495	$0.00
G8730	Pain assessment documented as positive using a standardized tool and a follow-up plan is documented	0%	696	$0.00
G8417	Bmi is documented above normal parameters and a follow-up plan is documented	0%	456	$0.00
G9744	Patient not eligible due to active diagnosis of hypertension	0%	15	$0.00
G8950	Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented	0%	453	$0.00
G9906	Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy)	0%	48	$0.00
1036F		0%	76	$0.00
1123F		0%	14	$0.00
G8428	Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given	0%	99	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMOHAJER, POUYA (OWNER)